Omer Bayraktar is a Group Leader at the Wellcome Sanger Institute , leading research in the Cellular Genomics Programme. His work focuses on decoding human brain cellular diversity using spatial transcriptomics , imaging , and functional screening to study neural complexity in health and disease. Bayraktar's educational background includes a PhD from HHMI under Chris Doe, investigating neural diversity development in Drosophila , followed by postdoctoral work at University of California, San Francisco and University of Cambridge as a Life Sciences Research Foundation Fellow. He developed a spatial transcriptomic pipeline during his postdoc to analyze astrocyte heterogeneity in the cerebral cortex. His research explores neural cell type mapping , glial-neuronal interactions , and cellular pathways in neurodevelopmental disorders . Recent publications emphasize 3D tissue mapping , multi-omic integration , and computational tools like Cell2fate and WebAtlas. His work bridges neurogenetics and computational biology to advance understanding of human tissue ecosystems. Bayraktar's lab collaborates with the Human Cell Atlas initiative and develops technologies such as automated histology pipelines and highly-multiplexed smFISH for molecular cell typing. His team also investigates glia-based therapies and astrocyte functional heterogeneity in neurodevelopmental contexts. Key scientific contributions include: Discovering astrocyte layer patterns independent of neuronal laminae Developing cell2location for spatial cell mapping Characterizing Drosophila neural stem cell models with human relevance Notable awards include the Life Sciences Research Foundation Fellowship during his postdoctoral training. His current group includes a PhD student , Senior Data Scientists , and Bioinformaticians .
Lars Engstrand is a Professor in infection control at Karolinska Institutet, heading the Translational Microbiome Research and Pandemic Preparedness group within the Department of Microbiology, Tumor and Cell Biology. His research spans multiple disciplines with a focus on translational microbiome research and pandemic preparedness. Engstrand's research interests center on understanding the human microbiome's role in health and disease, particularly in women's reproductive health and gastroenterology. His group has established multiple large-scale clinical studies including SweMaMi (Swedish Maternal Microbiome project), BASIC (associations between microbiota and preterm birth), VaMiGyn (Vaginal Microbiota in Gynaecological health), and several others investigating the vaginal microbiome's relationship to pregnancy outcomes, HPV infection, and cervical cancer. His team also conducts significant research on gut microbiome in inflammatory bowel disease and colorectal conditions through projects like PopCol and KOLBIBAKT. Analysis of Engstrand's most recent publications reveals a strong focus on the relationship between microbiome composition and women's health outcomes. His research consistently examines how vaginal, gut, and oral microbiomes influence pregnancy complications, preterm birth, HPV infection, and mental health during pregnancy. The work often employs large cohort studies with comprehensive sampling strategies across multiple body sites and time points, providing robust data for understanding microbiome dynamics in health and disease. Engstrand leads the Microbiome Exploration and Development for Intervention (MEDI) initiative and the National Pandemic Center (NPC) at Karolinska Institutet. The NPC conducted large-scale sequencing during the COVID-19 pandemic and has amassed over 1.5 million samples. His research group includes multiple specialized teams focusing on culturomics, bioinformatics, labcore operations, women's health research, and pandemic preparedness.
Kenneth Hoehn is an Assistant Professor in the Department of Biomedical Data Science at the Geisel School of Medicine, Dartmouth College. As a computational immunologist with expertise in evolutionary biology, he develops computational evolutionary approaches to trace cellular lineages, particularly B cells, in contexts such as infection, vaccination, cancer, and autoimmune diseases. His research focuses on understanding adaptive immunity in conditions like COVID-19 Food allergies Myasthenia gravis through collaborations with experimental teams. Key projects include: Phylogenetic modeling of B cell responses Evolutionary signatures in immune repertoires Tracking B cell dissemination in autoimmune diseases Epigenetic regulation of memory B cells Recent publications highlight trends in single-cell immunology , phylogenetic inference , and computational tools for analyzing B cell dynamics. His lab at Dartmouth integrates evolutionary genetics with high-resolution immune profiling.
Mona Singh is a Professor of Computer Science at Princeton University, with affiliations to the Lewis-Sigler Institute for Integrative Genomics and the Department of Molecular Biology. She has been a faculty member since 1999. Ph.D., Massachusetts Institute of Technology, 1995 A.B. and S.M. degrees in Computer Science from Harvard University Her research focuses on computational molecular biology, integrating machine learning and algorithms to analyze biological networks, protein interactions, and mutational impacts. Key areas include DNA/RNA binding prediction, protein structure analysis, and network-based disease gene discovery. Her recent work highlights trends in protein language models, kinase-substrate prediction, and equitable MHC binding algorithms. These span sub-fields like structural bioinformatics, network biology, and functional genomics. Scientific Awards: Presidential Early Career Award for Scientists and Engineers (PECASE) Rheinstein Junior Faculty Award ACM Fellow (2019) ISCB Fellow (2018) She has taught an introductory computational biology course with Professor Coleen Murphy, covering sequence analysis, phylogenetics, and network reconstruction. Her group has developed tools like dPUC , nCOP , and DiffMut . Her lab collaborates with institutions including Carnegie Mellon, Duke University, and the Broad Institute, advancing applications in cancer genomics, metabolic disease, and precision medicine.
Joel Weadge is an Associate Professor in the Biology Department at Wilfrid Laurier University , Waterloo, Ontario. His research focuses on bacterial biofilms, glycobiology, and protein structure-function relationships. Contact: jweadge@wlu.ca , Office: BA425 (Bricker Academic). Education: PhD in Microbiology (University of Guelph, 2006) BSc (Hons) in Microbiology (University of Guelph, 2000) Research Interests center on bacterial biofilms as virulence factors in pathogens like E. coli and Salmonella . Key areas include: Structural and functional characterization of biofilm proteins (cellulose, curli fimbriae) Enzymology of carbohydrate modifications (acetylation, phosphoethanolamine transfer) Developing therapeutics targeting biofilm synthesis Biopolymer applications for medical/industrial use Publications highlight studies on Pseudomonas and Salmonella biofilm mechanisms, glycosyltransferases, and carbohydrate-active enzymes, with methodologies spanning X-ray crystallography to high-throughput biofilm profiling. Labs and Teams: The Weadge Lab investigates biofilm roles in food/water security and oral health, utilizing enzymology, mass spectrometry, and structural biology. Current members include graduate students, technicians, and research assistants.
Raphael Franzini serves as Associate Professor of Medicinal Chemistry at the University of Utah, actively contributing to the Biological Chemistry PhD Program. His research pioneers innovative chemical approaches for therapeutic development, with dual focus on DNA-encoded library technologies and bioorthogonal drug delivery systems. His educational foundation includes an M.S. from the Swiss Federal Institute of Technology (Lausanne) and a Ph.D. from Stanford University. This training underpins his group's multidisciplinary methodology combining organic synthesis, bioconjugation, computational modeling, and advanced imaging techniques. Dr. Franzini's research program centers on two transformative areas: First, advancing DNA-encoded library screening through computational integration to identify leads for challenging targets like Tankyrase and Sirtuin 6, with recent work addressing false negatives in machine learning prediction. Second, developing novel bioorthogonal release chemistry using isonitrile-tetrazine reactions for spatiotemporally controlled drug activation, validated in zebrafish models. His group emphasizes both technological innovation and therapeutic translation, with chemistry designed to minimize off-target effects in solid tumors. Analysis of his 15 most recent publications reveals escalating integration of computational methods with experimental library screening, alongside refinement of bioorthogonal release kinetics. The work spans chemical biology, medicinal chemistry, and pharmaceutical sciences, with growing emphasis on machine learning for library data interpretation and in vivo validation of drug-release systems. Dr. Franzini maintains an active research laboratory that provides comprehensive training in cutting-edge drug discovery methodologies. His group culture prioritizes both scientific innovation and researcher development, with projects spanning from fundamental reaction kinetics to therapeutic applications. The lab's infrastructure supports organic synthesis, molecular imaging, and computational analysis for advancing precision therapeutics.
Mike Kirby is a Professor at the Kahlert School of Computing, University of Utah. He also holds adjunct professorships in the Department of Bioengineering and the Department of Mathematics. His current roles include leadership in scientific computing and informatics initiatives, including former directorships of the Utah Informatics Initiative (2019-2023) and the Multi-Scale Multidisciplinary Modeling of Electronic Materials (MSME) Collaborative Research Alliance (2016-2022). He has extensive experience in strategic research initiatives, including serving as Assistant Vice President for Research (2024-2025). Education: Dr. Kirby earned a PhD in Applied Mathematics (2002) and MS in Computer Science (2001) from Brown University, and a BS in Applied Mathematics and Computer Science from Florida State University (1997). Research Interests: Focus on large-scale scientific computing, physics-informed machine learning, computational science and engineering, high-order numerical methods, and visualization. His work bridges applied mathematics and computer science to address real-world engineering challenges. Publications: Over 150 peer-reviewed articles, including high-impact contributions in journals like Journal of Computational Physics and SIAM Journal on Scientific Computing . Recent work emphasizes machine learning for differential equations, topology optimization under uncertainty, and multi-fidelity modeling. Awards: Recognized for leadership in computational science and informatics, including contributions to University of Utah’s Clery Compliance Program. Advising & Grants: Supervised over 50 graduate students and postdocs. Secured funding from NSF, DOE, and industry partnerships, totaling millions in research grants. Active in interdisciplinary collaborations across engineering, materials science, and medicine. Labs/Teams: Scientific Computing and Imaging (SCI) Institute, Utah Informatics Initiative, and the Center for Multiscale Modeling of Electronic Materials (MSME).
Xiaoyu Cai is an Assistant Professor at the Department of Medicine, Loyola University Chicago, specializing in lung regeneration, aging biology, and stem cell plasticity. Her research focuses on the molecular mechanisms governing alveolar type 2 (AT2) stem cell dynamics during aging and chronic lung diseases. Education: Bachelor of Medicine (Peking University, 2012), Master of Science (Peking University, 2015), PhD in Biology of Aging (USC & Buck Institute, 2021) Key Research Areas: Lung regeneration, inflammation resolution, stem cell aging, 3D organoid cultures Methodologies: Single-cell multiome, mouse genetics, multicellular organoid systems Collaborations: Translational partnerships with clinical teams for bench-to-bedside applications Dr. Cai's recent work explores lineage plasticity in aged lung stem cells, ferroptosis suppression via CRISPR screens, and cellular aging atlases across species. She previously held a postdoctoral position at Genentech Inc. and maintains a professional lab website. Contact: xcai2@luc.edu | Office: CTRE 123
Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.
Dr. Igor V. Pivkin is a Full Professor at the Institute of Computing within the Faculty of Informatics at the Università della Svizzera italiana (USI) in Lugano, Switzerland. His academic journey includes degrees from Novosibirsk State University (B.Sc./M.Sc. Mathematics), Brown University (M.Sc. Computer Science and Ph.D. Applied Mathematics), and postdoctoral research at MIT's Department of Materials Science and Engineering. His research focuses on multiscale/multiphysics modeling , numerical methods , and large-scale simulations of biological and physical systems. Key areas include biophysics, cellular/molecular biomechanics, stochastic modeling, and coarse-grained molecular simulations. He leverages high-performance computing (HPC) and particle-based methods to address complex biological phenomena. His work spans diverse applications, from understanding cellular mechanosensitivity and biofilm engineering to modeling cancer cell behavior and red blood cell dynamics in the spleen. His contributions bridge computational science, biotechnology, and biomedical research. He has published extensively in top-tier journals, with recent work advancing automated biofilm analysis, deep learning for microbial classification, and systems biology approaches to metal bioleaching. His lab collaborates on interdisciplinary projects, emphasizing computational innovation for real-world biological challenges.
Konstantinos Kalogeropoulos is an Assistant Professor at the Department of Biotechnology and Biomedicine, Technical University of Denmark (DTU), leading research at the Cell Diversity Lab. His work bridges proteomics, computational biology, and snake venom research. Current projects: "The Proteomic Landscape during Influenza Infection" (2022-2025) Supervisor for PhD projects on protease network rewiring in psoriasis and wound exudate degradomics Research interests include: Proteomic analysis of inflammatory diseases Snake venom toxin structure prediction Extracellular matrix biomechanics De novo peptide sequencing algorithms Computational modeling of protease networks Recent article trends demonstrate his work in • Database-free proteomics (InstaNovo/InstaNexus) • Snake venom pathophysiology (V-ToCs clustering) • Inflammatory disease biomarkers (psoriasis, impaired healing) • Extracellular matrix mechanics (fibronectin tension, gut inflammation) Advising: Supervises PhD students Polhaus, C. J. M. and Haack, A. M., focusing on protease networks and wound healing.
Jethro Johnson is an Innovation Track Principal Investigator at the Kennedy Institute of Rheumatology and Deputy Director of the Oxford Centre for Microbiome Studies (OCMS) at the University of Oxford. His work integrates computational genomics and microbiome research to explore host-microbiome interactions in health and disease. PhD in Nutritional Ecology (University of Auckland, 2012) MRC Career Development Fellowship Former postdoctoral researcher at Jackson Laboratory for Genomic Medicine Research focuses on: Mechanistic understanding of gut microbiome impacts on metabolic diseases Multi-omic data integration for host-microbiome studies Computational approaches to microbiome analysis Methodological developments in 16S rRNA gene profiling Publications emphasize microbiome-disease associations, methodological innovations, and computational genomics applications across human and mouse models. Key themes include metabolic dysfunction, immune interactions, and microbial diversity analysis. Scientific recognition includes: MRC Career Development Fellowship in Computational Genomics As OCMS Deputy Director, he contributes to advancing microbiome research infrastructure and collaborative projects while leading his own computational genomics group at the Kennedy Institute.
Anders Krogh is a Professor at the Department of Computer Science, University of Copenhagen, and also holds a position at the Department of Public Health in the Section for Health Data Science and AI. He serves as the head of the Center for Health Data Science (HeaDS) in the Faculty of Health and Medical Sciences. Previously, he was affiliated with the Department of Biology at the University of Copenhagen until 2020. Dr. Krogh earned his PhD in theoretical physics but transitioned into machine learning and bioinformatics during his doctoral studies. His research spans both theoretical foundations and practical applications in these fields. He is particularly renowned for his pioneering work on hidden Markov models for biological sequences, which has had significant impact in computational biology. In recent years, Krogh's research has focused on deep generative models applied to gene expression data and other biomedical applications. His work bridges computer science with healthcare, developing AI-driven approaches for precision medicine, cancer diagnostics, and analysis of complex biological systems. His current research integrates machine learning with quantum computing applications in biomolecular modeling. Analysis of his recent publications reveals a strong trend toward applying artificial intelligence to healthcare challenges, particularly in rare diseases, cancer diagnostics, and personalized medicine. His work increasingly incorporates federated learning approaches to address privacy concerns while enabling collaborative research across institutions. There's also a growing emphasis on quantum computing applications in biomolecular modeling and drug discovery. As head of the Center for Health Data Science, Krogh leads interdisciplinary research efforts that bring together computer scientists, medical researchers, and clinicians. His team develops novel computational frameworks like MOSAIC for multimodal analysis of rare cancers and multiDGD for multi-omics data integration. These tools are designed to translate AI innovations into clinical practice while addressing the unique challenges of medical data.
Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.
Dr. Rong Fan is the Harold Hodgkinson Professor of Biomedical Engineering and Professor of Pathology at Yale University. His research focuses on developing and applying single-cell and spatial omics technologies to study immune systems, cancer, and aging. His lab has pioneered technologies like the IsoCode microchip for high-throughput protein profiling, and spatial multi-omics platforms (e.g., DBiT-seq, spatial-ATAC-seq) to analyze tissue complexity at cellular resolution. He co-founded IsoPlexis, Singleron Biotechnologies, and AtlasXomics to commercialize these innovations. Education: PhD in Chemistry from UC Berkeley (2006), B.S. in Applied Chemistry from University of Science and Technology of China (1999). Postdoctoral training at Caltech before joining Yale in 2010. Research interests include CAR-T cell therapy optimization, spatial epigenomics, and multi-omics integration. Key achievements include discovering biomarkers predictive of CAR-T efficacy and defining spatial genomic landscapes in cancer and neuroinflammation. Awards: NSF CAREER Award, Packard Fellowship, election to AIMBE, CASE, and NAI. Serves on advisory boards for Bio-Techne and Yale Ventures. Active in training future scientists via the Yale Biomedical Engineering and Yale School of Medicine programs.
.png)
